Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with COP-1 in multiple sclerosis.

M B Bornstein1, A Miller, S Slagle

  • 1Department of Neurology/Neurosciences, Albert Einstein College of Medicine, New York, NY 10461.

Neurology
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delphi study to develop a core outcome set for inpatient pain assessment after cesarean delivery.

Anaesthesia, critical care & pain medicine·2025
Same author

Is the Relationship between Short Interpregnancy Interval and Preterm Birth Related to a Short Cervix?

American journal of perinatology·2017
Same author

A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·1999
Same author

Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated.

Cephalalgia : an international journal of headache·1993
Same author

Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients.

Critical care medicine·1992
Same author

Lung function testing: selection of reference values and interpretative strategies.

The American review of respiratory disease·1992
Same journal

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

Neurology·2026
Same journal

Association of Changes in Intrinsic Capacity With Cognitive Decline and Dementia: A Prospective Cohort Study.

Neurology·2026
Same journal

Role of the Upper Motor Neuron in the Generation of Fasciculations in Early Disease Stages of Amyotrophic Lateral Sclerosis.

Neurology·2026
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
See all related articles

Cop-1, a polypeptide preparation, is explored for its potential in treating multiple sclerosis (MS). It stimulates myelin basic protein (MBP) to suppress experimental allergic encephalomyelitis (EAE), an animal model of MS.

Area of Science:

  • Neuroimmunology
  • Demyelinating Diseases
  • Pharmacology

Background:

  • Myelin basic protein (MBP) is a key component of the myelin sheath.
  • Experimental allergic encephalomyelitis (EAE) serves as an animal model for multiple sclerosis (MS).
  • MBP's role in EAE induction and suppression is context-dependent (adjuvant vs. saline).

Purpose of the Study:

  • To investigate Cop-1, a polypeptide preparation, for its therapeutic potential in multiple sclerosis (MS).
  • To evaluate the mechanism of Cop-1 in modulating the immune response related to myelin basic protein (MBP).

Main Methods:

  • Administration of Cop-1, a polypeptide preparation.
  • Assessment of its effects on myelin basic protein (MBP) and experimental allergic encephalomyelitis (EAE).

Related Experiment Videos

Main Results:

  • Cop-1 is designed to stimulate myelin basic protein (MBP).
  • MBP in Freund's complete adjuvant induces EAE, while MBP in saline suppresses EAE.
  • This differential effect of MBP provides a rationale for Cop-1's use in MS.

Conclusions:

  • Cop-1's mechanism involves stimulating MBP, potentially offering a therapeutic strategy for MS.
  • The study supports the rationale for using Cop-1 in managing multiple sclerosis based on MBP's immunomodulatory properties.